JP2025506681A5 - - Google Patents
Info
- Publication number
- JP2025506681A5 JP2025506681A5 JP2024548391A JP2024548391A JP2025506681A5 JP 2025506681 A5 JP2025506681 A5 JP 2025506681A5 JP 2024548391 A JP2024548391 A JP 2024548391A JP 2024548391 A JP2024548391 A JP 2024548391A JP 2025506681 A5 JP2025506681 A5 JP 2025506681A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- eye
- sequence
- raav particles
- unit dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310865P | 2022-02-16 | 2022-02-16 | |
| US63/310,865 | 2022-02-16 | ||
| US202263316705P | 2022-03-04 | 2022-03-04 | |
| US63/316,705 | 2022-03-04 | ||
| PCT/US2023/062531 WO2023158990A1 (en) | 2022-02-16 | 2023-02-14 | Method of reducing cst fluctuation in neovascular amd by a recombinant adeno-associated virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506681A JP2025506681A (ja) | 2025-03-13 |
| JP2025506681A5 true JP2025506681A5 (https=) | 2026-02-24 |
Family
ID=85570182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548391A Pending JP2025506681A (ja) | 2022-02-16 | 2023-02-14 | 組み換えアデノ随伴ウイルスによる血管新生ａｍｄにおけるｃｓｔ変動の低減方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4479098A1 (https=) |
| JP (1) | JP2025506681A (https=) |
| KR (1) | KR20240161978A (https=) |
| AU (1) | AU2023221321A1 (https=) |
| CA (1) | CA3244250A1 (https=) |
| IL (1) | IL314762A (https=) |
| MX (1) | MX2024010002A (https=) |
| WO (1) | WO2023158990A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| EP4653536A3 (en) | 2017-03-17 | 2026-02-25 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| WO2021050094A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| HRP20260137T1 (hr) * | 2019-09-11 | 2026-03-13 | Adverum Biotechnologies, Inc. | Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept |
-
2023
- 2023-02-14 WO PCT/US2023/062531 patent/WO2023158990A1/en not_active Ceased
- 2023-02-14 EP EP23710626.5A patent/EP4479098A1/en not_active Withdrawn
- 2023-02-14 KR KR1020247030971A patent/KR20240161978A/ko active Pending
- 2023-02-14 AU AU2023221321A patent/AU2023221321A1/en active Pending
- 2023-02-14 IL IL314762A patent/IL314762A/en unknown
- 2023-02-14 CA CA3244250A patent/CA3244250A1/en active Pending
- 2023-02-14 EP EP25188887.1A patent/EP4682163A3/en active Pending
- 2023-02-14 JP JP2024548391A patent/JP2025506681A/ja active Pending
-
2024
- 2024-08-15 MX MX2024010002A patent/MX2024010002A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547541A5 (https=) | ||
| JP2024515459A5 (https=) | ||
| JP2025506383A5 (https=) | ||
| FI4027983T3 (fi) | Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla | |
| AU2025271125A1 (en) | Methods for treating or preventing ophthalmological conditions | |
| JP2021503914A5 (https=) | ||
| Emerson et al. | Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema | |
| JP2025084976A5 (https=) | ||
| JP2025506681A5 (https=) | ||
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| JP2022522776A5 (https=) | ||
| Sobh et al. | Safety and efficacy of adeno-associated viral gene therapy in patients with retinal degeneration: a systematic review and meta-analysis | |
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| JP2020526514A5 (https=) | ||
| JP2020537637A5 (https=) | ||
| JP2022545967A5 (https=) | ||
| JP2021511030A5 (https=) | ||
| JP2024517143A5 (https=) | ||
| JP2022062153A (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP2024511024A (ja) | ２１－ヒドロキシラーゼ欠損症の遺伝子治療 | |
| WO2021050094A1 (en) | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept | |
| JP2025509568A5 (https=) | ||
| US12233113B2 (en) | Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency | |
| JP2020522524A5 (https=) | ||
| JP2024148177A (ja) | アフリベルセプトをコードするａａｖ２バリアントを使用する眼内血管新生疾患を処置する方法 |